Current status of nanomaterial-based treatment for hepatocellular carcinoma

被引：90

作者：

Baig, Badriya ^{[1
]}

Halim, Sulafa Abdel ^{[2
]}

Farrukh, Aaminah ^{[1
]}

Greish, Yaser ^{[2
]}

Amin, Amr ^{[1
]}

机构：

[1] UAE Univ, Dept Biol, Al Ain, U Arab Emirates

[2] UAE Univ, Dept Chem, Al Ain, U Arab Emirates

来源：

BIOMEDICINE & PHARMACOTHERAPY | 2019年 / 116卷

关键词：

Hepatic carcinoma; Nanoparticles; Synthetic nanoparticles; Natural nanoparticles; Surface functionalization; MESOPOROUS SILICA NANOPARTICLES; SERUM-ALBUMIN NANOPARTICLES; IRON-OXIDE NANOPARTICLES; NANO-ANTIOXIDANT THERAPY; DRUG-DELIVERY SYSTEM; CARBON NANOTUBES; POLYMERIC NANOPARTICLES; LIPOSOMAL DOXORUBICIN; SILVER NANOPARTICLES; CANCER-DIAGNOSIS;

D O I：

10.1016/j.biopha.2019.108852

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Cancer continues to be the leading cause of death worldwide. Hepatocellular carcinoma (HCC), a prominent form of liver cancer, is the second leading cause of cancer-related deaths, thanks to the lack of efficient diagnostic tools and consequently late diagnosis and to the scarce of available suitable treatments. Thus, novel approaches to treat HCC are in demand. The fast-growing field of nanotechnology offers infinite possibilities to design materials in the nanoscale with unique properties due to their high surface area and small size. Nanotechnology enabled scientists to design drug delivery systems that serve multiple purposes including treatment, diagnostics and imaging. This review provides an update on the overall concept and potential of cancer nanotechnology; highlights the advances made particularly toward therapeutic nanomaterials targeting HCC. Obstacles hindering further development of nanomaterials -mediated cancer therapy will also be discussed.

引用

页数：12

共 140 条

[61] Estimating cost savings from early cancer diagnosis [J].